Skip to main content
SpringerLink
Log in

Dosimetric study of radium-223 chloride and 153Sm-EDTMP for treatment of bone metastases using MCNPX code and available experimental data

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

Radium-223 chloride is an alpha emitter radiopharmaceutical which recently has been used for treatment of bone metastases. Absorbed and equivalent doses of 223RaCl2 were studied using MCNPX Monte Carlo code in a phantom consisted of bone marrow, bone and soft tissue. 153Sm-EDTMP as a beta emitter was also simulated for comparison with 223RaCl2. Results show that by injection of 100 µCi 223RaCl2 against 70 mCi 153Sm-EDTMP to a 70 kg adult man, equivalent dose of metastatic bone can be increased about six times without significant increase in delivered dose to healthy tissues. These results demonstrated acceptable agreement with experimental data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Twicross RG, Fairfield S (1982) Pain in advanced cancer. Pain 14:303–310

    Article  Google Scholar 

  2. Serafini AN (2001) Therapy of metastatic bone pain. J Nucl Med 42:895–906

    CAS  Google Scholar 

  3. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243–6249

    Article  Google Scholar 

  4. Campa JA, Rayne R (1992) The management of intractable bone pain: a clinician’s perspective. Semin Nucl Med 22:3–10

    Article  Google Scholar 

  5. Bahrami-Samani A, Bagheri R, Jalilian AR, Shirvani-Arani S, Ghannadi-Maragheh M, Shamsaee M (2010) Production, quality control and pharmacokinetic studies of 166Ho-EDTMP for therapeutic applications. Sci Pharm 78:423–433

    Article  CAS  Google Scholar 

  6. Bagheri R, Jalilian AR, Bahrami-Samani A, Mazidi M, Ghannadi-Maragheh M (2011) Production of holmium-166 DOTMP: a promising agent for bone marrow ablation in hematologic malignancies. Iran J Nucl Med 19:12–20

    CAS  Google Scholar 

  7. Banerjee S, Chakraborty S, Das T, Kothari K, Samuel G, Venkatesh M, Pillai MRA, Mathew B, Sarma HD, Chaudhari PR (2005) 177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: novel agent for bone pain palliation and their comparison with 153Sm-EDTMP. Founder’s Day Special Issue, 22–35

  8. Ritter MA, Cleaver JE, Tobias CA (1977) High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 266:653–655

    Article  CAS  Google Scholar 

  9. Ramdahl T, Larsen RH (2006) Targeted alpha emitters in tumor therapy. Drug Discov Dev 20:36–38

    Google Scholar 

  10. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005) First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11:4451–4459

    Article  CAS  Google Scholar 

  11. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH (2003) Targeting of osseous sites with α-emitting 223Ra: comparison with the α-emitting 89Sr in mice. J Nucl Med 44:252–259

    CAS  Google Scholar 

  12. Pfennig G, Klewe-Nebenius H, Seelmann-Eggebert W (1995) Karlsruher Nklidkarte, 6th edn. Longman Press, London

    Google Scholar 

  13. Shultis JK, Faw RE (2004) An MCNP primer. Department of mechanical and nuclear engineering, Kansas State University

  14. Strigari L, Sciuto R, D’Andrea M, Pasqualoni R (2007) Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation. Eur J Nucl Med Mol Imaging 34:1031–1038

    Article  CAS  Google Scholar 

  15. Giladi M, Milgrom C, Simkin A, Stein M, Kashtan H, Margulies J, Rand N, Chisin R, Steinberg R, Aharonson Z, Kedem R, Frankel VH (1987) Stress fractures and tibial bone width. J Bone Joint Surg Br 69:326–329

    CAS  Google Scholar 

  16. Sunderland S (1938) The quadrate tubercle of the femur. J Anat 72:309–312

    CAS  Google Scholar 

  17. International Commission on Radiation Units and Measurements (1989) Tissue substitutes in radiation dosimetry and measurements. ICRU Report 44 Bethesda, ICRU, MD

  18. International Commission on Radiation Units and Measurements (1992) Photon, electron, proton and neutron interaction data for body tissues. ICRU Report 46 Bethesda, ICRU, MD

  19. Brenner W, Kampen WU, Kampen AM, Henze E (2001) Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 42:230–236

    CAS  Google Scholar 

  20. Farhangh M, Holmes RA, Volkert WA, Logan KW, Singh A (1992) Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 33:1451–1458

    Google Scholar 

  21. Bayouth JE, Macey DJ, Kasi LP, Fossella FV (1994) Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 35:63–69

    CAS  Google Scholar 

  22. Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, Ketring AR (1989) Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 30:1814–1818

    CAS  Google Scholar 

  23. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG (1989) Samarium-153 EDTMP therapy of disseminated skeletal metastases. Eur J Nucl Med 15:784–795

    Article  CAS  Google Scholar 

  24. Li L, Liang Z, Deng H, Kuang A, Tan T, Luo S (2002) Sm-153 EDTMP bone uptake rate and its relation to therapeutic effect. Chin Med J 115:1096–1098

    CAS  Google Scholar 

  25. Henriksen G, Hoff P, Alstad J, Larsen RH (2001) 223Ra for endoradiotherapeutic applications prepared from an immobilized 227Ac/227Th source. Radiochim Acta 89:661–666

    Article  CAS  Google Scholar 

  26. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH (2002) Significant antitumor effect from bone-seeking, α particle-emitting radium-223 demonstrated in an experimental skeletal metastases model. Cancer Res 62:3120–3125

    CAS  Google Scholar 

  27. Coleman R, Flamen P, Naume B, Jerusalem G, Garcia C, Piccart M, Bryan-Tear CGO, Aksnes AK (2011) An open label, phase IIa, non-randomized study of radium-223 in breast cancer patients with bone-dominant disease no longer considered suitable for endocrine therapy. Cancer Res 71(Suppl. 3):497

    Google Scholar 

  28. Suominen MI, Rissanen JP, Käkönen R, Mumberg D, Ziegelbauer K, Halleen JM, Scholz A (2012) Alpharadin (Radium-223 chloride) completely prevents tumor growth in bone and increases survival in a mouse model of breast cancer bone metastases in preventive and micro-metastatic settings. Cancer Res 72(Suppl 1) Abstract nr 5712

  29. Flamen P, Coleman R, Naume B, Jerusalem G, Garcia C, Aksnes AK, Piccart M (2013) [18F] FDG PET: changes in uptake as a method to assess radium-223 dichloride (Ra-223) response in bone metastases of breast cancer patients with bone-dominant disease. J Nucl Med 54(Suppl. 2):647

    Google Scholar 

  30. European medicines agency, committee for medicinal products for human use (2013) Assessment report of Xofigo: 31 EMA/CHMP/578779/2013

  31. Harbert JC (1987) Nuclear medicine therapy. Thieme Medical, New York

    Google Scholar 

  32. Lewington VJ (2005) Bone seeking radionuclides for therapy. J Nucl Med 46:38–47

    Google Scholar 

  33. Bayer Health Care Pharmaceuticals Inc (2013) Wayne, NJ 07470. Reference ID: 3308326

  34. International Commission on Radiological Protection (1965) Report of the task group on reference man. ICRP Report 23 Oxford, Pergamon Press, England

  35. International Commission on Radiological Protection (2003) Relative biological effectiveness, radiation weighting and quality factor. ICRP Publication 92 Ann. ICRP 33

Download references

Author information

Authors and Affiliations

  1. Faculty of Energy Engineering and Physics, Amirkabir University of Technology, PO Box 15875-4413, Tehran, Iran

    R. Bagheri & H. Afarideh

  2. Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, PO Box 14155-1339, Tehran, Iran

    M. Ghannadi-Maragheh, A. Bahrami-Samani & S. P. Shirmardi

Authors
  1. R. Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Afarideh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Ghannadi-Maragheh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Bahrami-Samani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. P. Shirmardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Afarideh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bagheri, R., Afarideh, H., Ghannadi-Maragheh, M. et al. Dosimetric study of radium-223 chloride and 153Sm-EDTMP for treatment of bone metastases using MCNPX code and available experimental data. J Radioanal Nucl Chem 303, 1991–1998 (2015). https://doi.org/10.1007/s10967-014-3641-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-014-3641-9

Keywords

Search

Navigation